Continuous infusion of ceftazidime in cystic fibrosis. [Lancet. 1989] - PubMed

loading

Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. [Eur J Pediatr. 2000]
Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
Rappaz I, Decosterd LA, Bille J, Pilet M, Bélaz N, Roulet M. Eur J Pediatr. 2000 Dec; 159(12):919-25.
To the editor: Is it safe to administer a continuous infusion of ceftazidime (Fortum) prepared for 24 hours in cystic fibrosis (CF) patients? [Pediatr Pulmonol. 2002]
To the editor: Is it safe to administer a continuous infusion of ceftazidime (Fortum) prepared for 24 hours in cystic fibrosis (CF) patients?
Plasse JC, Chabloz C, Terrier A, Bellon G. Pediatr Pulmonol. 2002 Mar; 33(3):232-3.
Continuous infusion of ceftazidime in cystic fibrosis. [Lancet. 1989]
Continuous infusion of ceftazidime in cystic fibrosis.
David TJ, Devlin J. Lancet. 1989 Jun 24; 1(8652):1454-5.
Review [Strategy of antibiotic therapy in the course of chronic Pseudomonas aeruginosa infection]. [Rev Mal Respir. 2003]
Review [Strategy of antibiotic therapy in the course of chronic Pseudomonas aeruginosa infection].
Bassinet L. Rev Mal Respir. 2003 Apr; 20(2 Pt 2):S118-28.
Review The treatment of pulmonary infection in cystic fibrosis. [Scand J Infect Dis Suppl. 1995]
Review The treatment of pulmonary infection in cystic fibrosis.
Webb AK. Scand J Infect Dis Suppl. 1995; 96:24-7.

Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. [P T. 2011]
Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. P T. 2011 Nov; 36(11):723-63.
High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. [Ann Pharmacother. 2010]
High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.
Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC, Wilson WH, Drusano GL, Walsh TJ. Ann Pharmacother. 2010 May; 44(5):929-35. Epub 2010 Apr 6.
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. [Antimicrob Agents Chemother. 1...]
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Antimicrob Agents Chemother. 1997 Sep; 41(9):2053-6.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Continuous infusion of ceftazidime in cystic fibrosis.
Continuous infusion of ceftazidime in cystic fibrosis.
Lancet. 1989 Aug 12 ;2(8659):385.

PubMed
2566015[uid] (1)
PubMed
Liver transplantation in cystic fibrosis.
Liver transplantation in cystic fibrosis.
Lancet. 1989 May 13 ;1(8646):1073.

PubMed
Clinical manifestations of human parvovirus B19 in adults.
Clinical manifestations of human parvovirus B19 in adults.
Arch Intern Med. 1989 May ;149(5):1153-6.

PubMed
2541666[uid] (1)
PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed